Daniel J Renouf
BC Cancer · BC Cancer - Vancouver · BCCA - Vancouver Cancer Centre, Vancouver BC, Canada
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Daniel J Renouf as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 08:06 UTC. Open this list on ClinicalTrials.gov
- N/ANCT06574620 · Using Tumour DNA and Proteins to Better Understand How Pancreatic Cancer Responds to TreatmentBritish Columbia Cancer Agency · recruiting · Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma, Borderline Resectable Pancreatic Ductal Adenocarcinoma · principal investigator
- Ph1/Ph2NCT03450018 · A Study of SLC-0111 and Gemcitabine for Metastatic Pancreatic Ductal Cancer in Subjects Positive for CAIXBritish Columbia Cancer Agency · terminated · Metastatic Pancreatic Ductal Adenocarcinoma · principal investigator
- Ph2NCT03297606 · Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)Canadian Cancer Trials Group · recruiting · Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors · study chair
- Ph1NCT03217253 · Tazemetostat in Treating Patients With Metastatic or Unresectable Solid Tumors or B-Cell Lymphomas With Liver DysfunctionNational Cancer Institute (NCI) · withdrawn · Ann Arbor Stage III B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage IV B-Cell Non-Hodgkin Lymphoma, Metastatic Malignant Solid Neoplasm · principal investigator
- Ph2NCT02978547 · The Effects of Neoadjuvant Metformin on Tumour Cell Proliferation and Tumour Progression in Pancreatic Ductal AdenocarcinomaBritish Columbia Cancer Agency · unknown · Resectable Pancreatic Ductal Adenocarcinoma · principal investigator
- N/ANCT02869802 · Prospectively Defining Metastatic Pancreatic Ductal Adenocarcinoma Subtypes by Comprehensive Genomic AnalysisBritish Columbia Cancer Agency · recruiting · Cancer, Pancreatic Cancer · principal investigator
- Ph2NCT02651415 · Phase II Study of Perindopril and Regorafenib in mCRCBritish Columbia Cancer Agency · completed · Metastatic Colorectal Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 08:06 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- North American Star ConsortiumUM1CA186644 · NCI · UNIVERSITY HEALTH NETWORK · PI Philippe Bedard, Kevin D Courtney, Steven Grant, Salma Jabbour, Jeffrey Lancet, Devalingam Mahalingam, Lillian L Siu, JONATHAN C TRENT · fiscal years 2014 to 2026Named on NCT03217253
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 08:06 UTC. The ranking covers the 200 most relevant of 21 PubMed records, and a shared surname and initials can bring in a namesake. All 21 on PubMed
- Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer.Cancer Discov · 2020298 citationsRCR 11.1
- A Phase 1 Study of SLC-0111, a Novel Inhibitor of Carbonic Anhydrase IX, in Patients With Advanced Solid Tumors.Am J Clin Oncol · 2020224 citationsRCR 10.9
- 143 citationsRCR 8.6
- Genome and Transcriptome Biomarkers of Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors.Clin Cancer Res · 202174 citationsRCR 3.1
- A phase I/II study of the Src inhibitor saracatinib (AZD0530) in combination with gemcitabine in advanced pancreatic cancer.Invest New Drugs · 201245 citationsRCR 1.1
- 39 citationsRCR 7.3
- A phase II study of erlotinib in gemcitabine refractory advanced pancreatic cancer.Eur J Cancer · 201429 citationsRCR 0.8
- 25 citationsRCR 1.1
- Phase IB study of ziv-aflibercept plus pembrolizumab in patients with advanced solid tumors.J Immunother Cancer · 202222 citationsRCR 1.2
- Safety and Antitumor Activity of a Novel aCD25 Treg Depleter RG6292 as a Single Agent and in Combination with Atezolizumab in Patients with Solid Tumors.Cancer Res Commun · 202522 citationsRCR 4.2